Clinical Trials
5 trialsNCT02123823 2025-07-15
BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer
Boehringer Ingelheim
Phase 1 Completed
NCT01870505 2024-12-09
BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT02392611 2020-12-29
Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer
Gilead Sciences
Phase 1 Completed
NCT01597193 2019-05-08
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
Pfizer
Phase 1 Completed
NCT01938846 2019-01-04
BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors
Boehringer Ingelheim
Phase 1 Completed